Please assess the completion status of the following clinical trial:

Trial Title: Atazanavir/Ritonavir Maintenance Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* On first antiretroviral regimen, including at least 2 NRTIs and 1 PI, for at least 48 weeks immediately prior to study entry~* CD4 count of 250 cells/mm3 or greater~* Viral load less than 50 copies/ml within 30 days prior to entry~* Willing to use acceptable methods of contraception~Exclusion Criteria:~* Current or prior use of an NNRTI~* Certain PI mutations~* Hepatitis B infection within 90 days prior to study entry~* Certain therapies or medications within 30 days prior to study entry~* Heartbeat abnormalities or symptoms potentially related to heart block, such as unexplained fainting, dizziness, or palpitations, occurring within 180 days prior to study entry~* Drug or alcohol use or dependence that would interfere with adherence to the study requirements~* Serious illness requiring systemic treatment or hospitalization until the participant either completes therapy or has been clinically stable on therapy for at least 14 days prior to study entry~* Allergy or sensitivity to study medications or their formulations~* Current involuntarily incarceration for treatment of either a mental or physical illness~* Treatment for an active AIDS-defining opportunistic infection within 30 days prior to screening~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).